Search

Your search keyword '"Susan H. Fox"' showing total 318 results

Search Constraints

Start Over You searched for: Author "Susan H. Fox" Remove constraint Author: "Susan H. Fox"
318 results on '"Susan H. Fox"'

Search Results

201. A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

202. A writing device improves writing in primary writing tremor

203. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

204. Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease

205. Small intestinal bacterial overgrowth in Parkinson's disease

206. Parkinson’s Disease: Advanced Disease, Motor Complications, and Management

210. Frontal Lobe Gait Apraxia

214. Parkinson’s Disease with Psychosis

215. Psychogenic Movement Disorders

220. Dopa-Responsive Dystonia

221. Chorea

224. Whom to Refer for Surgery?

227. Multiple System Atrophy

231. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset

232. The serotonergic system in motor and non-motor manifestations of Parkinson's disease

234. Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice

235. Drug treatments for the neuropsychiatric complications of Parkinson's disease

236. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques

237. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

238. Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD

239. The meaning of a 'hippo' response on the Montreal Cognitive Assessment in Parkinson's disease

240. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

241. Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment

242. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset

243. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

244. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

245. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease

246. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

247. The serotonergic system in Parkinson's disease

248. l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment

250. Doctor - how quickly will my Parkinson's progress?

Catalog

Books, media, physical & digital resources